Quantcast
Home > Quotes > DFFN

Diffusion Pharmaceuticals Inc. Common Stock (DFFN) Quote & Summary Data

DFFN 
$2.86
*  
0.1403
4.68%
Get DFFN Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading DFFN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    DFFN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
2.125
Today's High / Low
$ 3.74 / $ 2.65
Share Volume
723,167
50 Day Avg. Daily Volume
16,028
Previous Close
$ 3.0003
52 Week High / Low
$ 31.2031 / $ 2.7768
Market Cap
9,656,015
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.05

Special Dividend Data

Special Dividend
N/A
Special Dividend Date
Dec. 14, 2018
Special Dividend Payment Date
N/A

Intraday Chart

Shares Traded

Share Volume:
723,167
50 Day Avg. Daily Volume:
16,028

Trading Range

The current last sale of $2.86 is 3.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.74 $ 31.2031
 Low: $ 2.65 $ 2.7768

Company Description (as filed with the SEC)

We are a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. We are developing our lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate ("TSC"), for use in the many cancer types in which tumor oxygen deprivation ("hypoxia") is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer's hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. TSC's helps regulate the diffusion of oxygen into oxygen-deprived cells (whether cancer cells or normal cells).  ... More ...  


Risk Grade

Where does DFFN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.44
Open Date:
Dec. 14, 2018
Close Price:
$ 2.86
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info